Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
Details : PPL-1 (monepantel) is a positive allosteric modulator of DEG-3/DES-2 type nicotinic acetylcholine receptors (nAChRs). It is being evaluated for motor neurone disease & amyotrophic lateral sclerosis.
Product Name : PPL-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable